BioXcel Therapeutics
CT - New HavenBiotechnology
Focus: BioXcel Therapeutics is a specialty biotech focused on novel sublingual thin film formulations for CNS and psychiatric indications, headquartered in New Haven, CT. The company generates 100% of revenue from IGALMI (dexmedetomidine), its FDA-approved sedation and delirium treatment.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About BioXcel Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow BioXcel Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Late-stage
5 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$65K Part DStable
Peak16.7yr
Sole revenue driver generating 100% of company sales; approved for sedation and delirium in ICU settings with extended exclusivity through 2043.
Help build intelligence for BioXcel Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.